BACKGROUND: Cause-and-effect associations between sevelamer hydrochloride (HCl) and mortality have yet to be clarified. The effects of sevelamer HCl on mortality, lipid abnormality and arterial stiffness were examined in patients with chronic kidney disease stage 5D. METHODS: The effects of sevelamer HCl were studied by a single-center cohort study that was conducted from January 1, 2005 to December 31, 2008 (n = 483). By the end of the study, 172 patients (Sevelamer group) had succeeded in continuing sevelamer HCl for >6 months (median 37 months), and 300 patients (Control group) had received calcium carbonate (n = 264) or no phosphate binder (n = 36). The mortality and other outcomes were compared between these two groups after matching by a propensity score calculated using age, gender, diabetes prevalence, and dialysis vintage. RESULTS: All-cause [hazard ratio (HR) 0.4, P = 0.02] and cardiovascular (CV)-cause [HR 0.29, P = 0.03] cumulative mortality were significantly lower in the matched Sevelamer group than in the matched Control group. The matched Sevelamer group showed increased high-density lipoprotein cholesterol (P = 0.003) and no change in pulse wave velocity (PWV) and ankle-brachial index (ABI), whereas the matched Control group showed increased serum low-density lipoprotein (LDL) cholesterol (P = 0.003), increased PWV (P = 0.03), and decreased ABI (P = 0.0009). Change in serum LDL cholesterol level correlated inversely with sevelamer HCl dosage (P = 0.02). CONCLUSIONS: Reduced mortality in patients with sevelamer HCl may, at least in part, be explained by an improvement in dyslipidemia and arterial stiffness by sevelamer HCl.
BACKGROUND: Cause-and-effect associations between sevelamer hydrochloride (HCl) and mortality have yet to be clarified. The effects of sevelamer HCl on mortality, lipid abnormality and arterial stiffness were examined in patients with chronic kidney disease stage 5D. METHODS: The effects of sevelamer HCl were studied by a single-center cohort study that was conducted from January 1, 2005 to December 31, 2008 (n = 483). By the end of the study, 172 patients (Sevelamer group) had succeeded in continuing sevelamer HCl for >6 months (median 37 months), and 300 patients (Control group) had received calcium carbonate (n = 264) or no phosphate binder (n = 36). The mortality and other outcomes were compared between these two groups after matching by a propensity score calculated using age, gender, diabetes prevalence, and dialysis vintage. RESULTS: All-cause [hazard ratio (HR) 0.4, P = 0.02] and cardiovascular (CV)-cause [HR 0.29, P = 0.03] cumulative mortality were significantly lower in the matched Sevelamer group than in the matched Control group. The matched Sevelamer group showed increased high-density lipoprotein cholesterol (P = 0.003) and no change in pulse wave velocity (PWV) and ankle-brachial index (ABI), whereas the matched Control group showed increased serum low-density lipoprotein (LDL) cholesterol (P = 0.003), increased PWV (P = 0.03), and decreased ABI (P = 0.0009). Change in serum LDL cholesterol level correlated inversely with sevelamer HCl dosage (P = 0.02). CONCLUSIONS: Reduced mortality in patients with sevelamer HCl may, at least in part, be explained by an improvement in dyslipidemia and arterial stiffness by sevelamer HCl.
Authors: Wolfgang C Winkelmayer; Robert J Glynn; Murray A Mittleman; Raisa Levin; Joseph S Pliskin; Jerry Avorn Journal: J Am Soc Nephrol Date: 2002-09 Impact factor: 10.121
Authors: W N Suki; R Zabaneh; J L Cangiano; J Reed; D Fischer; L Garrett; B N Ling; S Chasan-Taber; M A Dillon; A T Blair; S K Burke Journal: Kidney Int Date: 2007-08-29 Impact factor: 10.612
Authors: Geoffrey A Block; David M Spiegel; James Ehrlich; Ravindra Mehta; Jill Lindbergh; Albert Dreisbach; Paolo Raggi Journal: Kidney Int Date: 2005-10 Impact factor: 10.612
Authors: D Russo; I Miranda; C Ruocco; Y Battaglia; E Buonanno; S Manzi; L Russo; A Scafarto; V E Andreucci Journal: Kidney Int Date: 2007-09-05 Impact factor: 10.612
Authors: Wajeh Qunibi; Moustafa Moustafa; Larry R Muenz; David Y He; Paul D Kessler; Jose A Diaz-Buxo; Mathew Budoff Journal: Am J Kidney Dis Date: 2008-04-18 Impact factor: 8.860
Authors: Francesca Tentori; Margaret J Blayney; Justin M Albert; Brenda W Gillespie; Peter G Kerr; Jürgen Bommer; Eric W Young; Tadao Akizawa; Takashi Akiba; Ronald L Pisoni; Bruce M Robinson; Friedrich K Port Journal: Am J Kidney Dis Date: 2008-06-02 Impact factor: 8.860
Authors: Francesca Tentori; Justin M Albert; Eric W Young; Margaret J Blayney; Bruce M Robinson; Ronald L Pisoni; Takashi Akiba; Roger N Greenwood; Naoki Kimata; Nathan W Levin; Luis M Piera; Rajiv Saran; Robert A Wolfe; Friedrich K Port Journal: Nephrol Dial Transplant Date: 2008-11-21 Impact factor: 5.992
Authors: Netanya G Sandler; Xinyan Zhang; Ronald J Bosch; Nicholas T Funderburg; Andrew I Choi; Janet K Robinson; Derek M Fine; Robert W Coombs; Jeffrey M Jacobson; Alan L Landay; Daniel C Douek; Randall Tressler; Sarah W Read; Cara C Wilson; Steven G Deeks; Michael M Lederman; Rajesh T Gandhi Journal: J Infect Dis Date: 2014-05-26 Impact factor: 5.226
Authors: Luca Zanoli; Paolo Lentini; Marie Briet; Pietro Castellino; Andrew A House; Gerard M London; Lorenzo Malatino; Peter A McCullough; Dimitri P Mikhailidis; Pierre Boutouyrie Journal: J Am Soc Nephrol Date: 2019-04-30 Impact factor: 10.121